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Abstract 
The primary cilium is an essential structure for the mediation of numerous signaling pathways involved in the coordi-
nation and regulation of cellular processes essential for the development and maintenance of health. Consequently, 
ciliary dysfunction results in severe human diseases called ciliopathies. Since many of the cilia-mediated signaling 
pathways are oncogenic pathways, cilia are linked to cancer. Recent studies demonstrate the existence of a cilia-
regulated proteasome and that this proteasome is involved in cancer development via the progression of oncogenic, 
cilia-mediated signaling. This review article investigates the association between primary cilia and cancer with particu-
lar emphasis on the role of the cilia-regulated proteasome.
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Background
The precise coordination and regulation of cellular pro-
cesses is the basis for the development and the homeo-
stasis of a multi-cellular organism. To ensure this high 
precision, the cell makes use of a special structure that 
is observed as a 1–10-μm-long cellular evagination—the 
primary cilium. Simplified, the structure of the cilium 
consists of three different compartments—the basal body 
(BB), the axoneme, and the transition zone (TZ). The BB 
is a remodeled mother centriole from which the ciliary 
scaffold (axoneme) consisting of circularly arranged nine 
doublet microtubules arises. The intermediate region 
from the BB to the axoneme is a short area of 0.5  μm 
called TZ. The primary cilium plays a decisive role in the 
initiation of the molecular mechanisms underlying cellu-
lar processes like proliferation, apoptosis, migration, dif-
ferentiation, transcription, and the determination of cell 
polarity [1, 2]. Consequently, ciliary dysfunction results 
in severe diseases collectively summarized as ciliopathies. 
Well-known ciliopathies are: Joubert syndrome (JBTS), 
Leber’s congenital amaurosis (LCA), Senior–Løken 
syndrome (SLS), nephronophthisis (NPHP), Meckel–
Gruber syndrome (MKS), Bardet–Biedl syndrome (BBS), 
orofaciodigital syndrome type 1 (OFD1), Alström syn-
drome (ALS), Jeune asphyxiating thoracic dystrophy 
(JATD), Ellis–van Creveld syndrome (EVC), and sensen-
brenner syndrome (cranioectodermal dysplasia [CED]) 
[3]. Additionally, cilia are linked to cancer. The current, 
general view is that, on the one hand, primary cilia medi-
ate oncogenic signaling and, on the other hand, cilia are 
lost in some types of cancer. In this review article, the 
role of cilia in cancer development will be discussed with 
particular regard to the cilia-controlled proteasome. The 
focus is on the question: What is the significance of the 
cilia-regulated proteasome in terms of cancerogenesis?
Primary cilia, intercellular signaling, and cancer
Primary cilia mediate intercellular signaling pathways 
which are involved in the regulation of cellular processes 
and the formation and maintenance of all organs and 
structures within the human body. Cancer is character-
ized by uncontrolled cell division as well as an impaired 
ability to undergo apoptosis [4] and because it devel-
ops as a result of altered intra- and intercellular signal-
ing, disturbances of cilia-mediated signaling pathways 
can result in tumor formation [5–7]. While it seems as 
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if canonical WNT signaling is restricted by cilia [8–10], 
various publications have shown cilia-dependent media-
tion of sonic hedgehog (SHH), platelet-derived growth 
factor receptor-α (PDGFRα), NOTCH, transforming 
growth factor (TGF)-β, and non-canonical WNT signal-
ing (Fig. 1a–e) [8, 11–18].
Of all the investigated associations between primary 
cilia and signaling pathways, the relationship between 
primary cilia and SHH signaling is the best studied. In 
SHH signaling, the 12-pass transmembrane protein 
patched1 (PTCH1) is located in the ciliary membrane of 
vertebrates (Fig.  1a). When the SHH ligand binds to its 
receptor PTCH1, the SHH/PTCH1 complex leaves the 
cilium. As a consequence, the seven-transmembrane 
protein smoothened (SMO) is allowed to accumulate in 
the ciliary membrane and to invoke glioblastoma (GLI) 
transcription factors. Three GLI isoforms exist in ver-
tebrates—GLI1, 2, and 3. The GLI proteins regulate the 
expression of SHH target genes and thereby cell pro-
liferation, differentiation, survival and growth [19, 20]. 
While GLI1 exclusively functions as a constitutive tran-
scriptional activator [21, 22], GLI2 and GLI3 can serve 
as an activator or a repressor [23]. In the presence of 
SHH, full-length GLI2 (GLI2-185) and GLI3 (GLI3-190) 
proteins are converted into a transcriptional activator 
(GLI2-A and GLI3-A, respectively) most likely by modi-
fications [24, 25]. In the absence of SHH, the full-length 
proteins can be proteolytically processed into transcrip-
tional repressors (GLI2-R, also known as GLI2-78, and 
GLI3-R, also known as GLI3-83, respectively) [26]. It was 
reported that GLI3-R is the predominant repressor of 
SHH target gene transcription [26]. The ratio of activator 
and repressor forms regulates cellular processes depend-
ent on SHH signaling.
Similar to SHH signaling, activated PDGF receptors 
control cellular processes like proliferation, anti-apopto-
sis, migration, differentiation, actin reorganization, and 
cell growth [27–29]. The receptor PDGFRα localizes to 
cilia and undergoes dimerization and phosphorylation 
after being bound by its ligand PDGF-AA [14] (Fig. 1b). 
Stimulation of PDGFRα provokes the activation of signal 
transduction through the MEK 1/2-ERK 1/2 and AKT/
PKB pathways. In the absence of cilia, PDGFRα sign-
aling is inhibited [14]. Additionally, PDGFRα signal-
ing is restricted by the mammalian target of rapamycin 
(mTOR) signaling pathway [30–32], which is also asso-
ciated with cilia-mediated signaling. LKB1, a negative 
regulator of mTOR, localizes to cilia and its action leads 
to an accumulation of phosphorylated AMPK at the basal 
body [33]. In turn, the phosphorylation of AMPK results 
in the inhibition of mTOR signaling via a mechanism that 
is only poorly understood. Interestingly, deregulation 
of mTOR signaling has been described in many cancer 
types [34–36]. Previously, it has been demonstrated that 
NOTCH signaling depends on primary cilia [16, 17] 
(Fig.  1c). NOTCH signaling starts when the extracel-
lular domain of a NOTCH ligand, e.g., delta-like1–4 or 
jagged1–2, binds to the NOTCH receptor (NOTCH1–4) 
[37]. A ciliary localization was shown for NOTCH1 and 
NOTCH3 [16, 17]. After the binding event, the NOTCH 
receptor undergoes a three-step cleavage and finally 
releases the NOTCH intracellular domain (NIC). Fol-
lowing this, NIC enters the nucleus and interacts with 
its DNA-binding cofactor RBP-J/CBF1/CSL thereby acti-
vating NOTCH target genes. NOTCH signaling controls 
among other proliferation and differentiation [38].
Moreover, TGFβ signaling relates to cilia [18] (Fig. 1d). 
Both receptors of the pathway, TGFβ-RI and TGFβ-
RII, are located at the base of primary cilia. The ligand-
induced formation and activation of a heterotetrameric 
receptor complex composed of TGFβ-RI and TGFβ-
RII results in the phosphorylation and activation of the 
SMAD2 and SMAD3 proteins which are present at the 
ciliary base [18]. The phosphorylated SMADs 2 and 3 
associate with a co-SMAD called SMAD4 that is also 
detectable at the base of cilia. Subsequently, the complex 
consisting of SMAD2, 3, and 4 enters the nucleus and 
activates TGFβ target genes. TGFβ target genes control 
cellular processes like proliferation, differentiation, mor-
phogenesis, tissue homeostasis, and regeneration [39].
Primary cilia are also connected to WNT signal-
ing [40], which can be classified as canonical (β-catenin 
dependent) or non-canonical (β-catenin independent). 
In the inactive state of the canonical WNT pathway, a 
destruction complex consisting of adenomatous polypo-
sis coli (APC) and AXIN triggers the phosphorylation of 
β-catenin by casein kinase 1 (CK1) and glycogen synthase 
kinase 3 (GSK3) (Fig.  1e). Afterwards, β-catenin gets 
phosphorylated, ubiquitinated, and finally degraded [41]. 
The WNT/β-catenin pathway becomes initiated by bind-
ing of WNT ligands to frizzled (FZ) receptors and low 
density lipoprotein-related proteins 5/6 (LRP 5/6) and 
leads to the activation of the cytoplasmatic phosphopro-
tein disheveled (DSH). Subsequently, DSH recruits the 
destruction complex to the plasma membrane, thereby 
inhibiting phosphorylation of β-catenin. This operation 
of DSH enables β-catenin to translocate into the nucleus 
for activating target gene transcription. Several processes 
are controlled by canonical WNT signaling: cell fate 
determination, migration, proliferation, tumor suppres-
sion, and self-renewal of stem and progenitor cells [42, 
43].
In contrast to canonical WNT signaling, the non-
canonical WNT pathway is less well understood. Hence, 
it is unknown, if β-catenin-independent WNT path-
ways function as different distinct pathways or if these 
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pathways form a large signaling network [44]. Like 
the canonical WNT pathway, it starts with a WNT 
ligand binding to the FZ receptor, but does not require 
the presence of LRP co-receptors or β-catenin. Non-
canonical WNT signals are mediated through intracel-
lular Ca2+ levels and involvement of RHO A, ROCK, 
and JNK kinase. These factors play an important role in 
the regulation and remodeling of the cytoskeleton and 
are greatly involved in the control of planar cell polarity 
(PCP). PCP is established by intercellular communication 
that regulates the composition of cells polarizing struc-
tures within the plane of a tissue, i.e., stereocilia bundle 
orientation in the inner ear [45]. In addition to managing 
cytoskeleton organization, non-canonical WNT signals 
regulate proliferation and migration [46].
The restriction of canonical WNT signals by cilia is 
likely, since DSH is constitutively phosphorylated in 
Kif3a-negative mice which are unable to assemble cilia 
[47]. However, non-canonical WNT signaling seems to 
Fig. 1 Cilia-mediated signaling pathways whose proper regulation is 
dependent on the proteasome and the structure of the proteasome. 
a–e SHH, PDGFRα, NOTCH, TGFβ, and canonical WNT signaling is 
transduced by primary cilia. a In the absence of the ligand SHH, SMO 
remains in cytoplasmic vesicles and is inhibited by PTCH1. As a result, 
GLI2 and GLI3 (forming a complex with SUFU) are phosphorylated 
most likely within the cilium and subsequently get proteolytically 
processed to their repressor forms (GLI2/3-R) by the proteasome at 
the ciliary base. In turn, GLI2/3-R translocate into the nucleus and 
represses the expression of SHH target genes. Importantly, GLI3 is 
the predominant repressor. When SHH binds to its receptor PTCH1, 
the SHH/PTCH1 complex leaves the cilium and PTCH1 is not able to 
inhibit the action of SMO any longer. Thereupon, SMO is transported 
into the cilium and converts the full-length forms of GLI2 and GLI3 
(GLI2/3-FL) into their activator forms. In the course of this conversion 
process, SUFU dissociates from the complex enabling the GLI2 and 
GLI3 activator forms to induce SHH target gene expression. b In the 
ciliary membrane, PDGFRα is bound by its ligand PDGF-AA and subse-
quently becomes dimerized and phosphorylated. The phosphorylation 
of PDGFRα induces the activation of the MEK 1/2-ERK 1/2 and AKT/
PKB signaling pathways. c Initiating NOTCH signaling, the extracellular 
domain of a NOTCH ligand (JAGGED or DELTA) binds to the NOTCH 
receptor which is located in the ciliary membrane. As a result, the 
NOTCH receptor undergoes a three-step cleavage and finally releases 
the NOTCH intracellular domain (NIC). NIC enters the nucleus and 
activates NOTCH target genes. d The receptors of the TGFβ pathway, 
TGFβ-RI and TGFβ-RII, are located at the ciliary base. When the TGFβ 
ligand binds to the receptors a heterotetrameric receptor complex 
composed of TGFβ-RI and TGFβ-RII is formed and activated. This 
activation results in the phosphorylation and activation of SMAD2 and 
SMAD3. The phosphorylated SMADs 2 and 3 associate with a co-SMAD 
called SMAD4. Afterwards, the complex consisting of SMAD2, 3, and 4 
enters the nucleus and activates TGFβ target genes. e In the inactive 
state of the canonical WNT pathway, a destruction complex consisting 
of APC and AXIN triggers the phosphorylation of β-catenin by GSK3. 
After this phosphorylation event, β-catenin gets ubiquitinated and 
finally degraded. In the active state, WNT ligands bind to FRIZZLED 
and LRP receptors leading to the activation of DSH. DSH recruits the 
destruction complex to the plasma membrane, thereby interfering 
phosphorylation of β-catenin. Afterwards, β-catenin translocates into 
the nucleus and activates canonical WNT target gene expression. Pri-
mary cilia restrict canonical WNT signaling because the ciliary protein 
KIF3A is able to inhibit the phosphorylation of DSH. f The proteasome 
consists of the catalytic 20S subunit and two regulatory 19S subunits. 
The 20S subunit displays a cylindrical arrangement of four stacked 
heptameric rings. Each ring is composed of seven α and β subunits, 
respectively. Only three subunits (PSMB8-10) display a proteolytic 
activity equipping the proteasome with trypsin-like, chymotrypsin-
like, and caspase-like abilities. The 19S subunit can be subdivided into 
two subcomplexes: a base complex (being constituted of six ATPases 
[PSMC1-6] and three non-ATPases [PSMD1, 2 and 4]) and a lid complex 
(consisting of nine non-ATPases [PSMD3, 6-8, 11-14, and SHFM1])
▸
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be mediated by primary cilia [8–10]. One core PCP gene 
product, van gogh-like 2 (VANGL2), was found in cilia 
[48]. The ciliary presence of VANGL2 [48] and the find-
ing that VANGL2 is essential for the transduction of 
WNT5a-induced signals to establish PCP [49] suggest 
that non-canonical WNT signaling might be mediated by 
cilia. This hypothesis is supported by data showing that 
disruption of BBS protein function leads to ciliary dys-
function along with perturbation of PCP [48] and that 
ciliopathy genes interact genetically with VANGL2 [48, 
50]. In summary, these data suggest that primary cilia 
mediate non-canonical WNT signals and limit canonical 
WNT signaling [51].
Dysregulation of any of these pathways could lead to 
oncogenesis. In many cases, upregulation of their tar-
get gene expressions led to an increased cell prolifera-
tion, which in turn caused tumorigenesis [52–56]. One 
of the best studied oncogenic signaling pathways is the 
SHH pathway which was already analyzed in combina-
tion with cilia in cancer cells [57, 58]. In 2009, Han et al. 
and Wong et  al. [59, 60] described the role of primary 
cilia in the development of medulloblastomas and basal 
cell carcinomas. In regard to SHH signaling, both groups 
showed that the absence of cilia can protect against 
tumorigenesis and, in addition, that the presence of cilia 
can be necessary for the induction of tumors. First, they 
induced tumorigenesis via a cell type-specific expression 
of an activated SMO protein. Then, they performed the 
experiments in mice that were unable to form cilia in the 
particular cell type for the formation of either medullo-
blastomas or basal cell carcinomas. In both cases, ciliary 
deficiency protected against SMO-induced tumorigen-
esis [59, 60].
Second, the same groups investigated the consequences 
of constitutively active GLI2 on tumorigenesis [59, 60]. 
In case of basal cell carcinoma development, constitu-
tively active GLI2 was sufficient to induce carcinogenesis 
[60], while, in case of medulloblastoma development, 
constitutively active GLI2 did not give rise to carcino-
genesis [59]. Importantly, the combination of constitu-
tively active GLI2 and loss of cilia led to the formation 
of medulloblastomas [59] giving circumstantial evidence 
that the additional decreased amount of GLI3-R caused 
by ciliary absence might be necessary to induce onco-
genesis. Accordingly, the activation of SHH target gene 
expression alone is not strong enough for driving the 
development of some cancer types, but in combination 
with an inhibited repression of SHH target gene expres-
sion by reducing the amount of GLI3-R, activation of 
SHH target gene expression is sufficient to induce onco-
genesis. Possibly, the reason for these differences is that 
the importance of GLI3-R is different in diverse cancer 
types. Perhaps, it is even the case that the efficiency of 
GLI3 processing is different in different cancer types and 
the amount of GLI3-R varies. A decisive factor for the 
proteolytic processing of GLI3 is the proteasome.
The proteasome and cancer
The proteasome functions as the catalytic component of 
the ubiquitin–proteasome system and consists of 19S and 
20S subunits (Fig. 1f ). Proteins destined to get degraded 
or proteolytically processed become phosphorylated 
and ubiquitinated. Polyubiquitin conjugation is real-
ized by a cooperation of an ubiquitin-activating enzyme 
(E1), an ubiquitin conjugation enzyme (E2), and an ubiq-
uitin ligase (E3). In search of molecular mechanisms 
underlying carcinogenesis, it was reported that while 
E1 was never found to be associated with tumor forma-
tion, deregulation of E2 and especially E3 was detected 
in tumors [61]. In some cases, E3 ligases are inactivated 
leading to a stabilization of oncogene products. In other 
cases, E3 ligases are overexpressed causing an increased 
degradation of tumor suppressor proteins [62]. Finally, 
ubiquitinated proteins bind to the 19S regulatory com-
plex. Hereafter, they are degraded by the multiple pepti-
dase activities containing 20S subunit [63]. Besides the 
degradation of proteins, the proteasome is able to pro-
teolytically process proteins. A well-studied process-
ing event is the transformation of full-length GLI3 into 
its shorter repressor form. This process depends on a 
three-part signal [64]. The first processing signal is the 
zinc finger domain of the GLI3 protein, which serves as 
a physical barrier to the proteasome. It prevents degrada-
tion of the GLI3 protein and is an essential prerequisite 
for GLI3 processing. Accordingly, the proteasome is not 
the factor which distinguishes degradation from pro-
cessing, but the protein which is degraded or processed 
determines its fate via its sequence. The linker sequence 
which expands between the zinc finger domain and the 
lysines of the degron sequence functions as the second 
processing signal. Most likely, the proteasome binds to 
the linker area, which is assumed to be a proteasome ini-
tiation region. The degron is the third processing signal 
and the starting point of proteasomal processing.
In addition to its role in SHH signaling, the proteasome 
is important for the proper course of several cilia-medi-
ated signaling pathways. It was reported that PDGFRα 
signaling is upregulated in cancer cells due to an elevated 
amount of PDGFRα [65]. In these cells, HSP90 and the 
co-chaperone CDC37 form a complex with PDGFRα, 
making it inaccessible to proteasomal degradation 
(Fig. 1b). Previously, it was reported that the amount of 
PDGFRα could also be decreased in kidney tumors, while 
the amount of mTOR is increased and mTOR signal-
ing is upregulated [30, 31, 66]. Because mTOR regulates 
PDGFRα signaling negatively by reducing the amount 
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of PDGFRα [30] and mTOR governs proteasomal activ-
ity positively [67], it is conceivable that mTOR controls 
the PDGFRα amount via regulating proteasomal activ-
ity. If this hypothesis is true, it could be possible that 
cancer with a high PDGFRα amount is characterized by 
downregulated mTOR signaling. As far as we know, the 
evidence for this possibility has not been found yet. The 
proteasome is also involved in the regulation of NOTCH 
signaling, because it controls the NIC amount [68, 69] 
(Fig.  1c). In lung adenocarcinoma cells, proteasomal 
degradation of NIC is impaired resulting in enhanced 
cell proliferation and hence tumorigenesis [70]. Further-
more, TGFβ signaling requires the services of the protea-
some. Phosphorylated SMAD2 and SMAD3, the central 
transducers of the pathway, are inactivated by proteaso-
mal degradation [71, 72] (Fig. 1d). Accordingly, reduced 
proteasomal degradation of these SMADs gives rise to 
hyperproliferative diseases like cancer [71]. As previ-
ously mentioned, canonical WNT signaling is most likely 
restricted by primary cilia [47]. At the base of these cilia, 
the proteasome degrades β-catenin that is phosphoryl-
ated at Ser33, Ser37, and Thr41 [47, 50] (Fig. 1e). In some 
tumors, this kind of phosphorylation is prevented by 
mutations resulting in a stabilization of β-catenin which 
then is able to activate the transcription of many onco-
genes [73, 74]. Consequently, canonical WNT signaling 
is not only restricted by primary cilia but also by protea-
somal degradation of β-catenin. As opposed to the just 
described signaling pathways, an essential role of the pro-
teasome in non-canonical WNT signaling has never been 
described.
In sum, a decreased proteasomal activity causes 
a deregulation of signaling pathways, leading to an 
increased cell proliferation resulting in the development 
of cancer. However, numerous studies show that protea-
somal activity is enhanced in cancer cells [75–89] rep-
resenting an obvious discrepancy. A plethora of point 
mutations in cancer genomes lead to a very high number 
of misfolded proteins [90]. It was hypothesized that the 
cell faces this enormous boost of useless and even harm-
ful proteins with enhanced proteasome-mediated deg-
radation [91]. Moreover, estimates suggest that 90  % of 
human solid tumors comprise cells with more than two 
copies of one or more chromosomes [92]. For this rea-
son, a huge surplus of proteins is produced in these cells 
resulting in a cellular protein imbalance [93, 94]. Conse-
quently, many proteins are not able to form a stable con-
formation and get degraded by the proteasome [95, 96]. 
Thus, cancer cells show an increased proteasomal activ-
ity due to various reasons. This phenomenon has been 
designated as “proteotoxic crisis” [91]. Based on this 
knowledge, proteasome inhibitors are used in anti-cancer 
therapies [97].
However, there is a unique class of cancer cells with a 
decreased proteasomal activity in which the use of pro-
teasome inhibitors would be counterproductive. Reduced 
proteasomal activity is a hallmark of several cancer 
stem cells (CSCs) [98–103]. In contrast, glioma stem-
like cells (GSCs) show an increase of proteasomal activ-
ity [104] suggesting that proteasomal activity may vary 
among types of CSCs. But it is doubtful whether GSCs 
belong to the group of CSCs because they maintain only 
some properties of CSCs [105]. CSCs (also known as 
cancer-initiating cells) are part of a new understanding 
in terms of tumorigenesis. In contrast to the “stochastic 
model” in which every cancer cell of a tumor is capable 
of repopulating the entire tumor because of its property 
of self-renewal, this model conveys the idea that only a 
small group of cancer cells (CSCs) within a tumor has the 
ability to repopulate the tumor and that the progeny of 
these cells loses this ability [106–109]. Even in the course 
of chemotherapy, CSCs are able to survive and initi-
ate the re-growth of tumors [110, 111]. Thus, CSCs are 
the reason for the resistance of tumors to conventional 
anti-cancer therapies. Consequently, it is a challenging 
task for the current research to develop new anti-cancer 
therapies which target CSCs [111]. In the development 
of this type of anti-cancer therapies, a broad spectrum 
of pharmaceutical compounds were tested. Interestingly, 
natural dietary compounds came into focus [112]. Since 
proteasomal activity is reduced in most CSCs and since 
the decisive signals thought to underlie the self-renewal 
mechanism of the CSCs are, inter alia, SHH signaling, 
PDGFRα signaling, NOTCH signaling, TGFβ signaling, 
and WNT signaling [106, 113–119], one of these com-
pounds is sulforaphane (SFN; 1-isothiocyanato-4(R)-
methylsulfinylbutane), an ingredient of broccoli, which 
functions as a proteasome activator [120]. In 2010, Li 
et al. [101] tested the effect of SFN on breast cancer cells. 
They came up with the conclusion that the SFN treat-
ment downregulated canonical WNT signaling by pro-
moting proteasomal degradation of β-catenin in CSCs. 
The SFN treatment eliminated breast CSCs [101], indi-
cating that the decreased proteasomal activity is essential 
for the survival of CSCs and that SFN could be an effec-
tive drug in anti-cancer stem cell therapies.
Primary cilia and the proteasome
After reviewing the connections between primary cilia 
and cancer, as well as the proteasome and cancer, the 
relationship between primary cilia and the protea-
some should be investigated in order to determine the 
molecular mechanisms underlying cancer development. 
As early as 2003, it was suggested that although protea-
somes exist almost ubiquitously within the cytoplasm 
and the nucleus, “their function is likely to be different 
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at different cellular locations” and that “this probably 
depends on post-translational modifications of protea-
somal subunits and on their association and interaction 
with specific regulatory proteins” [121]. In 2007, Ger-
des et  al. [50] reported that the ciliary protein BBS4 is 
involved in the proteasomal degradation of cytoplasmic 
β-catenin, the mediator of canonical WNT signaling. In 
the following years, interactions of a whole range of cili-
ary proteins with proteasomal components were identi-
fied (Table 1) indicating a possible link between cilia and 
the proteasome. In this context, it was shown that the 
ciliary proteins BBS1, BBS2, BBS4, BBS6, BBS7, BBS8, 
and OFD1 interact directly with different proteasomal 
components [122]. The loss of BBS4, BBS7, and OFD1 
leads to a reduced proteasomal activity, respectively, 
impairing intercellular signaling pathways [50, 122, 123]. 
In search of the molecular reason for the depleted pro-
teasomal activity, Liu et  al. [122] measured a decreased 
amount of different proteasomal components in the 
absence of BBS4 and OFD1, respectively, demonstrat-
ing that these proteins control the composition of the 
proteasome. Since all these proteins localize to the basal 
body which is equivalent to the mother centriole in cili-
ary absence, the authors of this study refer to the effect 
of these proteins on the “centrosomal proteasome” [122]. 
The existence of a centrosome-associated proteasome 
was already shown before [124, 125]. Thus, the question 
arises whether the cilium is important for proteasomal 
function or whether it rests on the centrosome alone to 
regulate proteasomal activity. Three components of the 
19S proteasomal subunit (PSMD2, PSMD3, and PSMD4) 
were detected at the BB of mouse embryonic fibroblast 
(MEF) cilia [126]. However, the detection of protea-
somal components at the BB is not sufficient to answer 
this question; it might be that the centrosomal and the 
putative ciliary proteasome (a proteasome that func-
tions cilia dependent) are one and the same. Remarkably, 
a component of the 20S proteasomal subunit (PSMA5) 
was found along the whole cilium increasing the likeli-
hood of a ciliary involvement in proteasome assembly or 
function [126]. Interestingly, the ubiquitin conjugation 
system has been described in flagella of the single-cell 
green alga Chlamydomonas reinhardtii but, in contrast 
to the cilia of MEFs, no proteasomal components were 
detected in these flagella [127] indicating that the poten-
tial ciliary proteasome developed later in evolution and 
might even be vertebrate specific. Using the G-LAP-Flp 
purification strategy in mammalian cell lines [128] which 
ensures high-confidence proteomics, numerous interac-
tions of the transition zone proteins INVS (also known as 
NPHP2), IQCB1 (also known as NPHP5), and RPGRIP1L 
(also known as FTM, NPHP8, or MKS5) with different 
components of the proteasome were detected [129]. It 
was already shown that these three proteins are located 
at the centrosomes during mitosis [126, 129–132] ena-
bling a putative interaction with a component of the cen-
trosomal proteasome. In Rpgrip1l-negative MEFs and 
limbs of mouse embryos, a reduced proteasomal activity 
was quantified at the ciliary base. In contrary to the situa-
tion in the absence of BBS4 and OFD1 which was charac-
terized by a reduced overall cellular proteasomal activity, 
RPGRIP1L deficiency results in a decreased proteasomal 
activity exclusively at the base of cilia (in ciliary absence, 
the proteasomal activity at centrosomes of Rpgrip1l−/− 
MEFs is unaltered) demonstrating the existence of a 
ciliary proteasome [122, 126]. This study could draw the 
attention from the connection between centrosome and 
proteasome to the link between primary cilia and protea-
some. Contrary to the situation in the absence of BBS4 
and OFD1 which was characterized by a depletion of 
proteasomal components, RPGRIP1L deficiency results 
in an accumulation of proteasomal 19S and 20S subunit 
components at the ciliary base [122, 126]. Another differ-
ence between these ciliary proteins is the choice of their 
proteasomal interaction partners. While RPGRIP1L and 
OFD1 have been shown to interact with components of 
the 19S proteasomal subunit, BBS4 interacts with com-
ponents of the 19S as well as 20S proteasomal subunits 
(Table 1). All these findings indicate that ciliary proteins 
use different mechanisms with which they regulate pro-
teasomal activity.
Mutations in RPGRIP1L, BBS4, and OFD1 give rise 
to very severe ciliopathies which often lead to death in 
men and mice [133–143]. These ciliary proteins regulate 
proteasomal activity [50, 122, 126] and the proteasome 
is involved in the development and function of numer-
ous organs and structures of the human body [144–146]. 
Therefore, reduced activity of the cilia-regulated protea-
some is a potential cause of ciliopathies. Appropriately, in 
silico studies using a systematic network-based approach 
to work out the “cilia/centrosome complex interac-
tome (CCCI)” revealed that the greatest community 
of the CCCI is composed of proteasomal components 
[147]. Thus, it is likely that the relationship between cili-
ary proteins and the proteasome is of great importance. 
Further evidence for this importance is given by rescue 
experiments in  vivo. The injection of proteasomal com-
ponent mRNA or SFN treatment restored defective con-
vergent extension and somatic definition in zebrafish 
embryos treated with bbs4 or ofd1 morpholinos [122]. 
Additionally, it could be shown that the introduction of 
a constitutively active Gli3-R protein (Gli3Δ699) rescues 
telencephalic patterning, olfactory bulb morphogenesis, 
and the agenesis of the corpus callosum in Rpgrip1l-nega-
tive mouse embryos [148, 149]. Together, these data dem-
onstrate that a decreased activity of the cilia-regulated 
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Table 1 Interactions between ciliary proteins and proteasomal components
Ciliary protein (localization) Proteasomal component (subunit) Cell type Source
BBS1 (basal body) PSMB1 (20S subunit) C57BL/6 testis [122]
BBS1 (basal body) RPN10 (19S subunit) C57BL/6 testis [122]
BBS1 (basal body) RPN13 (19S subunit) C57BL/6 testis [122]
BBS1 (basal body) RPT6 (19S subunit) C57BL/6 testis [122]
BBS1 (basal body) PA28 gamma (19S subunit) C57BL/6 testis [122]
BBS2 (basal body) PSMB1 (20S subunit) C57BL/6 testis [122]
BBS2 (basal body) RPN10 (19S subunit) C57BL/6 testis [122]
BBS2 (basal body) RPN13 (19S subunit) C57BL/6 testis [122]
BBS2 (basal body) RPT6 (19S subunit) C57BL/6 testis [122]
BBS2 (basal body) PA28 gamma (19S subunit) C57BL/6 testis [122]
BBS4 (basal body) PSMB1 (20S subunit) C57BL/6 testis [122]
BBS4 (basal body) RPN10 (19S subunit) C57BL/6 testis [122]
BBS4 (basal body) RPN13 (19S subunit) C57BL/6 testis [122]
BBS4 (basal body) RPT6 (19S subunit) C57BL/6 testis [122]
BBS4 (basal body) PA28 gamma (19S subunit) C57BL/6 testis [122]
BBS6 (basal body) PSMB1 (20S subunit) C57BL/6 testis [122]
BBS6 (basal body) RPN10 (19S subunit) C57BL/6 testis [122]
BBS6 (basal body) RPN13 (19S subunit) C57BL/6 testis [122]
BBS6 (basal body) RPT6 (19S subunit) C57BL/6 testis [122]
BBS6 (basal body) PA28 gamma (19S subunit) C57BL/6 testis [122]
BBS7 (basal body) PSMB1 (20S subunit) C57BL/6 testis [122]
BBS7 (basal body) RPN10 (19S subunit) C57BL/6 testis [122]
BBS7 (basal body) RPN13 (19S subunit) C57BL/6 testis [122]
BBS7 (basal body) RPT6 (19S subunit) C57BL/6 testis [122]
BBS7 (basal body) PA28 gamma (19S subunit) C57BL/6 testis [122]
BBS8 (basal body) PSMB1 (20S subunit) C57BL/6 testis [122]
BBS8 (basal body) RPN10 (19S subunit) C57BL/6 testis [122]
BBS8 (basal body) RPN13 (19S subunit) C57BL/6 testis [122]
BBS8 (basal body) RPT6 (19S subunit) C57BL/6 testis [122]
BBS8 (basal body) PA28 gamma (19S subunit) C57BL/6 testis [122]
INVS (transition zone + inversin compartment) PSMD9 (19S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMB1 (20S subunit) 3T3 [129]
IQCB1 (transition zone + basal body) PSMA3 (20S subunit) 3T3 [129]
IQCB1 (transition zone + basal body) PSMB6 (20S subunit) 3T3 [129]
IQCB1 (transition zone + basal body) PSMB5 (20S subunit) 3T3 [129]
IQCB1 (transition zone + basal body) PSMA6 (20S subunit) 3T3 [129]
IQCB1 (transition zone + basal body) PSMB7 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMA5 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMB6 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMA4 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMB2 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMB5 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMA7 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMA1 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMB3 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMB1 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSME4 (proteasome activator protein) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMA3 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMA7 (20S subunit) IMCD3 [129]
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proteasome is responsible for the development of cili-
opathies in these model organisms. Future studies should 
address if this is also true for human ciliopathies.
Does the cilia‑regulated proteasome play a role 
in the development of cancer?
Several studies have focused on the association between 
cancer and ciliary presence [150–160]. Since a reduced 
number of cilia was detected in different cancer types 
[57–60, 150–156, 158, 159, 161], it was reported that 
tumorigenesis results in a reduced cilia frequency in 
some cancer types. Until now, it is unknown why some 
cancer cell types possess cilia and others not (Table  2). 
Although the absence of cilia is able to correct effects of 
an oncogenic initiating event that lies upstream of ciliary 
action [59, 60], the loss of cilia is not the only solution 
to treat cancerogenesis. If the oncogenic initiating event 
lies downstream of ciliary action, therapeutic target-
ing of cilia would not help in the development of cancer 
therapies. Accordingly, genetic screening for the onco-
genic initiator might be the most important point to 
design effective anti-cancer therapies. In this context, it 
would be an interesting question for future investigations 
whether ciliary genes are mutated in patients suffering 
from cancer. It was previously reported that the ciliary 
gene RPGRIP1L might serve as a tumor suppressor gene 
because RPGRIP1L was downregulated in human hepa-
tocellular carcinoma [162]. Mechanistically, RPGRIP1L 
is thought to suppress tumor cell transformation in 
part by regulating MAD2, a mitotic checkpoint protein 
whose inactivation is realized by the proteasome [162, 
163]. Since knockdown of RPGRIP1L led to an increased 
amount of MAD2, the function of RPGRIP1L as a con-
troller of ciliary proteasome activity could be of great 
importance in the prevention of human hepatocellular 
carcinoma formation. Proteasomal activity seems to be 
an important factor in cancerogenesis, since proteaso-
mal activity is altered in many cancer types (Table 3) and 
the use of proteasome activators and inhibitors as anti-
cancer therapeutics showed promising results [100, 164, 
165]. In most cancer types, proteasomal activity is ele-
vated [75–89]. Until now, the reason for this increase is 
unknown. Since mutations of genes encoding ciliary pro-
teins led to a reduced proteasomal activity in ciliopathies 
of mice and zebrafishes [122, 126], it might seem as if 
mutations in these genes could only play a role in cancer 
Table 1 continued
Ciliary protein (localization) Proteasomal component (subunit) Cell type Source
IQCB1 (transition zone + basal body) PSMB4 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMA2 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMA6 (20S subunit) IMCD3 [129]
IQCB1 (transition zone + basal body) PSMB4 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMA1 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMA2 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMA3 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMA4 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMA5 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMA6 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMA7 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMB1 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMB2 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMB3 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMB5 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMB6 (20S subunit) RPE [129]
IQCB1 (transition zone + basal body) PSMB7 (20S subunit) RPE [129]
OFD1 (basal body) RPT6 (19S subunit) C57BL/6 testis [122]
RPGRIP1L (transition zone) PSMC2 (19S subunit) IMCD3 [129]
RPGRIP1L (transition zone) PSMC5 (19S subunit) IMCD3 [129]
RPGRIP1L (transition zone) PSMD11 (19S subunit) IMCD3 [129]
RPGRIP1L (transition zone) PSMD3 (19S subunit) IMCD3 [129]
RPGRIP1L (transition zone) PSMD2 (19S subunit) HEK293T [126]
RPGRIP1L (transition zone) PSMD2 (19S subunit) NIH/3T3 [126]
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types with reduced proteasomal activity. However, it 
was reported that RPGRIP1L controls the ciliary protea-
some in MDCK cells negatively opposing the findings 
in MEFs and embryonic mouse limbs [126, 166]. These 
findings as well as studies on cilia length argue for a cell 
type-specific function of RPGRIP1L allowing that muta-
tions in RPGRIP1L cause an increase of ciliary proteas-
ome activity in some organs and a concomitant reduction 
of this activity in other organs [126]. Theoretically, it is 
conceivable that an increased amount of ciliary proteins 
leads to enhanced proteasomal activity. In this regard, a 
recent study demonstrated that the overexpression of the 
RPGRIP1L domain, which interacts with the proteasomal 
component PSMD2, gives rise to an elevated activity of 
the ciliary proteasome [126]. What remains to be deter-
mined is if the increased proteasomal activity found in 
most cancer types could be due to impaired regulation of 
proteasomal activity by ciliary proteins. 
Another cancer cell type in which the cilia-regulated 
proteasome might play a leading role is the CSC. Since the 
loss of ciliary proteins BBS4, BBS7, OFD1, and RPGRIP1L 
resulted in a reduced proteasomal activity [50, 122, 123, 
126] and CSCs lack cilia in addition to a decreased pro-
teasomal activity [98–103, 150], it is quite possible that a 
reduction of cilia-regulated proteasomal activity causes 
the development and/or ensures the survival of most 
CSCs. However, this is more of a meta-analysis. The only 
kind of CSC reported to lack cilia was a medulloblastoma 
CSC [150]. Until now, data about the existence of cilia 
on other CSCs are missing. Consequently, the presence 
of cilia in CSCs of other cancer types needs to be inves-
tigated. To gain insight into the potential relationship 
between the cilia-regulated proteasome and cancerogen-
esis, it is necessary to perform comparative investigations 
focusing on the activity of the ciliary proteasome and the 
presence of cilia in cancer cells.
Table 2 Ciliary presence in different cancer types
Cancer type Cancer cell type Ciliary presence Cilia-associated information References
Yes No
Bladder cancer Urothelial cells; urothelial  
carcinoma (UC) cell lines
X Cilia-associated HH signaling mediates the prolifera-
tion and survival of human urothelial carcinoma 
(UC) cell lines and is required for UC tumor growth 
in vivo
[58]
Brain tumor Medulloblastomas X X* Anaplastic* medulloblastomas have few or no ciliated 
cells; cilia are present in most desmoplastic medul-
lablastoma but almost exclusively in tumors that 
have activation in either HH or WNT signaling
[59]
Breast cancer Breast cancer cells;  
breast cancer cell lines
X** X Absence of primary cilia; loss of primary cilia in all 




Cancer stem cells Medulloblastoma stem cells X CD15 + medulloblastoma cells lack primary cilia [150]
Colon cancer Colon epithelium cells X Decreased frequency of primary cilia in absence of 
TTLL3 linked to the development of human colo-
rectal carcinomas
[154]
Lung cancer Columnar epithelium;  
mucous columnar cells
X X*** Loss of cilia by change from normal ciliated columnar 
epithelium to mucous columnar cell in cases of 
non-terminal respiratory unit type adenocarci-
noma***
[155]
Skin cancer Melanocytes X**** X Decreased amount of primary cilia in melano-
cytes****; loss of primary cilia in melanoma cell lines
[156]
Ovarian cancer Epithelial ovarian cells X Reduced cilia frequency; deregulated Hh and 
platelet-derived growth factor receptor alpha 
(PDGFRα) signaling
[57]
Pancreatic cancer Pancreatic ductal cells;  
pancreatic cancer cell lines
X X Primary cilia were identified in pancreatic cancer cell 
lines and in 25 of 100 pancreatic ductal adenocarci-
noma (PDAC) cases; the presence of primary cilia is 
significantly associated with the prognosis of PDAC
[157]
Prostate cancer Prostatic epithelial cells X Reduced primary cilia frequency; tendency to shorter 
cilia
[158]
Renal cancer Renal cells; renal tumor parenchyma X Strongly reduced cilia frequency; the reduction in 
clear cell renal cell carcinomas (ccRCC) is signifi-
cantly stronger than in papillary renal cell carcino-
mas (pRCC)
[159–161]
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Conclusion
Oncogenic signaling pathways are mediated by primary 
cilia. Consequently, an association between primary cilia 
and cancer is very likely. Altered proteasomal activity is 
an often observed feature in cancer cells [75–89, 98–103] 
and it was demonstrated that ciliary proteins control pro-
teasomal activity [50, 122, 123, 126]. Previously, it was 
suggested that the dysfunction of the cilia-controlled pro-
teasome is only one contributory factor of the ciliopathic 
pathology [122]. Thus, an important purpose of future 
studies will be to reveal the impact of the cilia-regulated 
proteasome in human ciliopathies. This aim is closely 
related to the analysis of the cilia-regulated proteasomal 
activity in cancer. Consequently, cancer therapies could 
be advanced by targeting cilia. In the context of protea-
somal activity, SFN is a promising therapeutic agent for 
ciliopathies and any form of cancer in which proteasomal 
activity is reduced. It remains an open question whether 
the reduced activity in these cancer types corresponds to 
the cilia-controlled proteasomal activity. The answer to 
this question could extend the knowledge about onco-
genic factors in a significant direction. Interestingly, a 
characteristic of most CSCs is a decreased proteasomal 
activity [98–103] making it possible that new insights 
into the field of cilia and in particular, the cilia-regulated 
proteasome, help to understand the biology of tumor for-
mation and reformation as well as the therapeutic pos-
sibilities to treat various types of cancer. However, even 
if nearly all CSCs display a reduced proteasomal activ-
ity, most cancer types exhibit the exact opposite—an 
elevated proteasomal activity. There is scant evidence of 
ciliary dysfunction resulting in an increase of proteaso-
mal activity, but it does not seem to be impossible due to 
cell type-specific functions of ciliary proteins [126, 166]. 
In this regard, it would be helpful to know whether the 
higher proteasomal activity in cancer cells depends on 
“proteotoxic crisis” or not [91].
Based on the novelty of the relationship between the 
primary cilium and the proteasome, it is difficult to 
make a clear statement to the role of the cilia-regulated 
proteasome in cancerogenesis. However, this research 
topic is very promising and the relationship between 
the cilia-controlled proteasome and cancer holds enor-
mous potential for the development of new anti-cancer 
therapies.
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Bladder cancer Human bladder cancer cells; human T24 urinary bladder 
carcinoma cell line
X [75–77]
Brain tumor GBM stem-like cells; temozolomide-resistant glioma cell 
lines
X [104]
Breast cancer MCF-7 and MDA-MB-231 human breast cancer cells X [78]
Cancer stem cells Various cancer stem cells; human head and neck squamous 
cell carcinoma (HNSCC) cells; breast cancer stem cells 
(BCSCs)
X [98–103]
Colon cancer HCT116 colon adenocarcinoma cells; metastatic colorectal 
cancer tissue
X [79, 80]
Lung cancer Lung cancer cell lines (H460, A549 and H129) X [81, 82]
Skin cancer Various human and mouse tumor cell lines X [84]
Ovarian cancer Various ovarian cancer cell lines X [83]
Pancreatic cancer MIA-PaCa-2 human pancreatic cancer cells X [85]
Prostate cancer LNCaP (AD) and PC3 (AI) PCa cells X [86]
Renal cancer Renal cell carcinoma tissue; clear cell renal cell carcinoma 
(CCRCC) cell lines
X [87–89]
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type 1; PCP: planar cell polarity; PDGF: platelet-derived growth factor; PDGFRα: 
platelet-derived growth factor receptor-α; PSMA5: proteasome subunit alpha 
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